Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathwaysVincenzo Quagliariello, Nicola Maurea, Margherita Passariello et al.|Frontiers in Cardiovascular Medicine|2022Cited by 48
Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving ImmunotherapyMaria Laura Canale, Nicola Maurea, Andrea Camerini et al.|Advances in Therapy|2020Cited by 43
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in CardioncologyVincenzo Quagliariello, Nicola Maurea, Irma Bisceglia et al.|Cancers|2023Cited by 42
ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summaryLuigi Tarantini, Alessandro Inno, Michele Massimo Gulizia et al.|European Heart Journal Supplements|2017Cited by 30
Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionalsIrma Bisceglia, Furio Colivicchi, Luigi Tarantini et al.|Frontiers in Cardiovascular Medicine|2023Cited by 17